SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS OF TREATMENT BURDEN OUTCOMES ASSOCIATED WITH FARICIMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Author(s)
Martha Goodwin, MSc1, Kenneth Forsstrøm Jensen, MSc Econ2, Mohamed El Alili, PhD3, Fatma Khrouf, Sr., MASc, PhD4, Craig Keenan, MSc5.
1Roche Products Ireland Ltd, Dublin 24, Ireland, 2Roche Products Ltd, Copenhagen, Denmark, 3Roche Netherlands, Woerden, Netherlands, 4Inizio Ignite Putnam, Tunis, Tunisia, 5Inizio Ignite Putnam, Dublin, Ireland.
1Roche Products Ireland Ltd, Dublin 24, Ireland, 2Roche Products Ltd, Copenhagen, Denmark, 3Roche Netherlands, Woerden, Netherlands, 4Inizio Ignite Putnam, Tunis, Tunisia, 5Inizio Ignite Putnam, Dublin, Ireland.
OBJECTIVES: To systematically review and quantitatively synthesize evidence on injection frequency, treatment intervals, healthcare resource utilization (HCRU), and productivity outcomes associated with faricimab in treatment-naïve and previously treated patients with neovascular age-related macular degeneration (nAMD).
METHODS: MEDLINE, Embase, and Cochrane databases were searched from May 2025-March 2026 and supplemented with grey literature searches. Studies conducted in 15 selected countries evaluating faricimab in treatment-naïve or previously treated patients with nAMD were eligible. Interventional and observational studies reporting injection frequency, treatment intervals, HCRU, or productivity outcomes were included. Study selection, data extraction, and quality assessment were performed according to predefined criteria. Where feasible, outcomes were quantitatively synthesised using meta-analysis.
RESULTS: Of 391 records identified, 8 studies met the inclusion criteria. Most patients switched from anti-VEGF therapy to faricimab, while one study included treatment-naïve patients. Six studies reported outcomes over 12 months using a treat-and-extend regimen. Injection Frequency ( ≥1 Year): In mixed and previously treated populations, the mean number of injections ranged from 6.1-12.0 after switching to faricimab, compared to 8.7-38.5 injections reported with prior anti-VEGF therapies. In treatment-naïve patients, the mean was 7.8 injections. Treatment Intervals (12 Months): Following faricimab initiation, mean treatment intervals increased by 2.0-3.5 weeks. At 12 months, intervals reached 8.5 weeks in previously treated patients (vs. 4-5 weeks pre-switch) and 10.5 weeks in treatment-naïve patients. Long-Term Intervals: At 1.5-2.5 years of follow-up, mean treatment intervals extended further, ranging from 8.8-14.0 weeks.No studies reported HCRU or productivity outcomes.
CONCLUSIONS: Evidence suggests that faricimab is associated with longer treatment intervals and fewer injections in patients with nAMD in routine clinical practice, suggesting a reduced treatment burden compared with prior anti-VEGF treatment.
METHODS: MEDLINE, Embase, and Cochrane databases were searched from May 2025-March 2026 and supplemented with grey literature searches. Studies conducted in 15 selected countries evaluating faricimab in treatment-naïve or previously treated patients with nAMD were eligible. Interventional and observational studies reporting injection frequency, treatment intervals, HCRU, or productivity outcomes were included. Study selection, data extraction, and quality assessment were performed according to predefined criteria. Where feasible, outcomes were quantitatively synthesised using meta-analysis.
RESULTS: Of 391 records identified, 8 studies met the inclusion criteria. Most patients switched from anti-VEGF therapy to faricimab, while one study included treatment-naïve patients. Six studies reported outcomes over 12 months using a treat-and-extend regimen. Injection Frequency ( ≥1 Year): In mixed and previously treated populations, the mean number of injections ranged from 6.1-12.0 after switching to faricimab, compared to 8.7-38.5 injections reported with prior anti-VEGF therapies. In treatment-naïve patients, the mean was 7.8 injections. Treatment Intervals (12 Months): Following faricimab initiation, mean treatment intervals increased by 2.0-3.5 weeks. At 12 months, intervals reached 8.5 weeks in previously treated patients (vs. 4-5 weeks pre-switch) and 10.5 weeks in treatment-naïve patients. Long-Term Intervals: At 1.5-2.5 years of follow-up, mean treatment intervals extended further, ranging from 8.8-14.0 weeks.No studies reported HCRU or productivity outcomes.
CONCLUSIONS: Evidence suggests that faricimab is associated with longer treatment intervals and fewer injections in patients with nAMD in routine clinical practice, suggesting a reduced treatment burden compared with prior anti-VEGF treatment.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
SA13
Topic
Patient-Centered Research, Study Approaches
Topic Subcategory
Literature Review & Synthesis, Meta-Analysis & Indirect Comparisons
Disease
Sensory System Disorders (Ear, Eye, Dental, Skin)